Sales distribution of diabetic drugs in China 2018-2030, by category

Oral hypoglycemic drugs were the major diabetes medication category in China, accounting for about 60 percent of the market in 2018. Acarbose has been the bestselling oral antidiabetic medication in the country as it reduces glucose uptake mainly and is particularly suitable for the traditional Chinese diet high in carbohydrates. With its effectiveness at lowering blood sugar level, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) was expected to raise its market share significantly from two to 21 percent by 2030.

Market share of diabetic medication sales revenue in China in 2018 and estimates until 2030, by drug type

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until September 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

October 2019

Region

China

Survey time period

2018

Supplementary notes

*Estimate.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Diabetes in China"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.